Nicox SA announced that an affiliate of its licensee, Bausch + Lomb, has launched VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Mexico. Approval was obtained in Mexico in January 2020. Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones payments.